In a thought-provoking new interview featured in Brain Medicine, Dr. Gabriella Gobbi, a leading figure in psychiatry at McGill University, issues a stark warning about the current trajectory of psychiatric drug development. Gobbi, who holds the Canada Research Chair in Therapeutics for Mental Health and serves as President-Elect of the Collegium Internationale of Neuropsychopharmacology (CINP), argues that the promise of many innovative treatments is being stifled not by scientific shortcomings, but by the capital-driven frameworks dictating which drugs reach patients. This unvarnished critique underscores a systemic challenge embedded deeply within the pharmaceutical industry’s reliance on private investment, with profit motives often overshadowing urgent medical needs.
Dr. Gobbi’s concerns highlight a disconcerting reality: early-stage research funded through public grants frequently produces promising compounds, but the translational pipeline—encompassing toxicological profiling and costly first-in-human trials—depends heavily on venture capital with strict expectations for return on investment. This creates a bottleneck where potentially affordable and effective therapies may never advance beyond preliminary discovery. “We risk losing good, non-expensive treatments because a greedy, capitalistic system controls which drug will ultimately be brought to market,” Gobbi remarks, emphasizing the conflict between economic incentives and public health priorities.
The foundation for Dr. Gobbi’s impactful career is rooted in a personal history steeped in resilience and intellectual curiosity. Raised in Italy amidst a family legacy marked by sacrifice and a fervent commitment to education, her passion for neuroscience blossomed early. Inspired by neurobiological pioneers such as Rita Levi-Montalcini and grounded by exposure to both clinical and laboratory environments, Gobbi crafted a uniquely integrated approach to psychiatric research. Her journey through the often rigid academic hierarchies in 1990s Italy culminated with a decisive move to McGill, thanks to a pivotal mentorship opportunity with Professor Pierre Blier, setting the stage for decades of translational innovation.
Dr. Gobbi’s research portfolio exemplifies a bench-to-bedside philosophy, most notably in her investigation of cannabinoids and their impact on neuropsychiatric health. Beginning in the early 2000s, she observed adolescents who used cannabis develop severe depression characterized by profound anhedonia. This clinical pattern inspired a series of studies linking cannabinoid receptor activity with serotonin system dysregulation, laying important groundwork that correlated adolescent cannabis exposure with later depressive phenotypes in both animal models and human cohorts. These findings have not only amassed extensive academic citations but have also informed public policy, influencing Canadian legislative initiatives on cannabis regulation.
Parallel to her work on cannabinoids, Dr. Gobbi has been a pioneer in elucidating the role of the melatonin MT2 receptor—a relatively obscure target when her team first began exploring it in 2006. Her laboratory decoded the receptor’s distribution and vital function in regulating restorative non-REM sleep, as well as its modulation of neuropathic pain processes. Importantly, these mechanistic insights paved the way for the development of an MT2-selective partial agonist now poised for clinical investigation, highlighting how deep mechanistic work can translate into novel therapeutic avenues.
Since 2013, Gobbi’s team has also ventured into the emerging realm of psychedelic pharmacology, exploring the neurobiological underpinnings of substances like LSD, psilocybin, DMT, and 5-MeO-DMT. Their preclinical research elucidates anxiolytic and prosocial behavioral effects mediated via molecular pathways such as mTORC1 signaling. These investigations are complemented by burgeoning clinical trials aimed at identifying objective neurophysiological biomarkers to better understand psychedelic mechanisms in humans, situating Dr. Gobbi at the forefront of a rapidly evolving field with profound implications for psychiatric treatment.
Beyond her scientific achievements, Dr. Gobbi candidly addresses the pervasive gender inequities within academic science. From overt harassment to systemic disadvantages like inequitable administrative support and a skewed conference invitation culture, she paints a vivid picture of the ‘hidden tax’ imposed on women researchers. As the first female president of the CINP in its 70-year history, she has become a vocal advocate for structural reforms designed to recognize excellence without imposing additional burdens rooted in gender bias and caregiving responsibilities.
The interview also reveals a profoundly human side to Dr. Gobbi. She treasures a poignant letter from her late mother, a source of personal strength amidst the rigors of scientific endeavor. Her happiest moments emerge through the “eureka” instances of research—when elusive data synthesize into coherent narratives, unveiling nature’s secrets. Outside the laboratory, she finds solace paddling the Adriatic Sea or skiing in Quebec’s gentler springtime light, embodying a philosophy of perseverance, authenticity, and trust in the unfolding process of discovery.
Dr. Gobbi’s reflection on mentorship underscores a critical infrastructure gap within academia. She entered her professorial role lacking mentorship and formal training in leadership or grant writing, a gap she believes contributed to unnecessary challenges that could be mitigated with better systemic support. Her candid acknowledgement highlights how investment in mentorship and leadership development is essential not only for individual career progression but for fostering innovation and inclusion within scientific communities.
The broader implications of Dr. Gobbi’s insights resonate across the neuropsychopharmacology landscape, shedding light on the complexities that govern research translation in mental health therapeutics. Her work exemplifies the intricate dance between clinical observation and molecular neuroscience, bridging pathways from fundamental biology to clinical applications while challenging the economic and social frameworks that shape this journey. Her unflinching critique calls for a reconsideration of how scientific discoveries are shepherded to ensure that patient welfare—not financial gain—remains paramount.
This in-depth interview, part of the Genomic Press series “Innovators and Ideas,” enriches our understanding not only of the scientific breakthroughs that Dr. Gobbi has spearheaded but also of the cultural and structural dynamics influencing the future of psychiatric medicine. It invites the scientific community and the public alike to ponder how innovation can flourish in a system that better values both human health and equitable opportunity. As mental health challenges continue to mount globally, leaders like Gobbi illuminate pathways forward that merge rigorous science with compassionate advocacy.
Dr. Gabriella Gobbi’s story is a compelling narrative of scientific rigor, ethical clarity, and personal resilience. Her voice urges urgent reflection on the priorities shaping drug development and academic culture, making a vital contribution to conversations that will define psychiatry’s future. Her work serves as a beacon to researchers, clinicians, policymakers, and advocates striving to reconcile the promise of neuroscience with the realities of lived experience in mental health disorders.
As this interview becomes freely accessible in Brain Medicine, it offers a rare and expansive perspective on psychopharmacology—one that integrates molecular insights, clinical relevance, and sociocultural critique. For anyone invested in the future of brain medicine, Dr. Gobbi’s outlook is both a challenge and an inspiration, urging renewed commitment to a scientific ecosystem where innovation serves humanity above all else.
Subject of Research: People
Article Title: Gabriella Gobbi: Embracing psychiatry from bench to bedside
News Publication Date: 17-Mar-2026
Web References:
https://interviews.genomicpress.com/
https://doi.org/10.61373/bm026k.0015
References: The article references Dr. Gobbi’s body of research linking cannabinoid-serotonin interactions with depression, mechanistic studies on melatonin MT2 receptors, and psychedelic pharmacology studies, as well as public health policy impacts related to cannabis legislation.
Image Credits: Gabriella Gobbi, MD, PhD
